Hermanus Kieftenbeld Sells 34,905 Shares of Amyris, Inc. (NASDAQ:AMRS) Stock

Amyris, Inc. (NASDAQ:AMRS – Get Rating) CFO Hermanus Kieftenbeld sold 34,905 shares of the stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $2.34, for a total value of $81,677.70. Following the transaction, the chief financial officer now directly owns 266,655 shares of the company’s stock, valued at approximately $623,972.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Amyris stock traded down $0.12 during mid-day trading on Friday, hitting $2.38. The company’s stock had a trading volume of 4,186,317 shares, compared to its average volume of 6,133,438. The firm has a market capitalization of $760.92 million, a PE ratio of -1.93 and a beta of 1.66. Amyris, Inc. has a 1 year low of $1.47 and a 1 year high of $17.42. The company has a current ratio of 1.77, a quick ratio of 1.46 and a debt-to-equity ratio of 1.26. The stock’s fifty day moving average is $3.40 and its two-hundred day moving average is $4.47.

Amyris (NASDAQ:AMRS – Get Rating) last issued its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.13). The company had revenue of $57.71 million during the quarter, compared to the consensus estimate of $65.45 million. The business’s revenue for the quarter was down 67.4% compared to the same quarter last year. During the same period last year, the firm earned ($1.08) EPS. On average, equities analysts expect that Amyris, Inc. will post -0.85 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. Van ECK Associates Corp grew its position in Amyris by 378.0% in the fourth quarter. Van ECK Associates Corp now owns 4,732 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 3,742 shares during the period. Gordian Capital Singapore Pte Ltd purchased a new position in shares of Amyris during the fourth quarter worth $26,000. Hudock Inc. purchased a new position in shares of Amyris during the first quarter worth $31,000. Prospera Financial Services Inc purchased a new position in shares of Amyris during the first quarter worth $39,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Amyris during the fourth quarter worth $41,000. Institutional investors own 49.43% of the company’s stock.

Several equities research analysts recently commented on the company. StockNews.com assumed coverage on Amyris in a report on Thursday, March 31st. They issued a “sell” rating for the company. Piper Sandler assumed coverage on Amyris in a report on Wednesday, May 25th. They issued a “neutral” rating and a $2.50 price target for the company. Finally, Zacks Investment Research cut Amyris from a “hold” rating to a “sell” rating in a report on Monday, May 16th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.25.

Amyris Company Profile (Get Rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.

Read More